Respiratory Diseases

Tezepelumab FDA-approved for Self-administration by Patients with Severe Asthma
February 02, 2023

The approval offers patients the choice to administer the monoclonal antibody at home using a prefilled device or to continue to receive it in a clinical setting.

Adults with COPD Face Higher Risk of Death 1 Year after Surgery, New Study Finds
February 01, 2023

COPD was associated with a 61% increase in risk of death and 13% greater total costs in the year after surgery, according to a new study.

Respiratory Tripledemic 2022-23: Expert Update, Top Challenges
January 31, 2023

Distinguishing between influenza, COVID-19, and RSV and persuading vaccine-weary patients to get vaccinated are some of the challenges this season, says William Schaffner, MD.

Air Pollution Independently Linked to Asthma Exacerbation in Urban-dwelling Children
January 31, 2023

Asthma exacerbations in children living in low-income urban areas were significantly associated with reduced air quality and specific pollutants in a new analysis.

Moderna Reports Adult RSV Vaccine Efficacy of 84% in Phase 3 ConquerRSV Trial
January 18, 2023

The mRNA vaccine returned efficacy of 83.7% against RSV-associated lower respiratory tract disease defined by ≥2 symptoms and of 82.4% against disease defined by ≥3 symptoms.

FDA Grants BLA Review for Nirsevimab for RSV Prevention in Broad Infant Population
January 10, 2023

If approved, nirsevimab would be the first single-dose RSV preventative option for the broad newborn and infant population in the US.

Healthy Eating Patterns Associated with Reduced Risk of Mortality in Large Cohort Study
January 10, 2023

Adherence to several different healthy eating patterns was associated with reduced risk for all- and specific-cause mortality in a large prospective cohort study with 36 years of follow-up.

ACIP 2023 Vaccination Schedule Update, At-a-Glance
January 04, 2023

Among the CDC vaccine advisory group's recommendations are adding COVID-19 vaccines to the Vaccine for Children program and allowing PCV20 shots for those who previously received PCV13.

FDA Grants Priority Review to Pfizer’s RSV Vaccine Candidate for Older Americans
December 08, 2022

The FDA has granted priority review to a biologics license application for Pfizer’s respiratory syncytial virus vaccine candidate, RSVpreF, for adults aged ≥60 years.